Muscles of sarcopenic people show hypotrophic myofibers and infiltration with adipose and, at later stages, fibrotic tissue. The origin of infiltrating adipocytes resides in fibro-adipogenic precursors and nonmyogenic mesenchymal progenitor cells, and in satellite cells, the adult stem cells of skeletal muscles. Myoblasts and brown adipocytes share a common Myf5 + progenitor cell: the cell fate depends on levels of bone morphogenetic protein 7 (BMP-7), a TGF-β family member. S100B, a Ca 2+ -binding protein of the EF-hand type, is expressed at relatively high levels in myoblasts from sarcopenic humans and exerts anti-myogenic effects via NF-κB-dependent inhibition of MyoD, a myogenic transcription factor acting upstream of the essential myogenic factor, myogenin. Adipogenesis requires high levels of ROS, and myoblasts of sarcopenic subjects show elevated ROS levels. Here we show that: (1) ROS overproduction in myoblasts results in upregulation of S100B levels via NF-κB activation; and (2) ROS/NF-κB-induced accumulation of S100B causes myoblast transition into brown adipocytes. S100B activates an NF-κB/Ying Yang 1 axis that negatively regulates the promyogenic and anti-adipogenic miR-133 with resultant accumulation of the brown adipogenic transcription regulator, PRDM-16. S100B also upregulates BMP-7 via NF-κB/Ying Yang 1 with resultant BMP-7 autocrine activity. Interestingly, myoblasts from sarcopenic humans show features of brown adipocytes. We also show that S100B levels and NF-κB activity are elevated in brown adipocytes obtained by culturing myoblasts in adipocyte differentiation medium and that S100B knockdown or NF-κB inhibition in myoblast-derived brown adipocytes reconverts them into fusion-competent myoblasts. At last, interstitial cells and, unexpectedly, a subpopulation of myofibers in muscles of geriatric but not young mice co-express S100B and the brown adipocyte marker, uncoupling protein-1. These results suggest that S100B is an important intracellular molecular signal regulating Myf5 + progenitor cell differentiation into fusion-competent myoblasts or brown adipocytes depending on its levels. Cell Death and Differentiation (2017) 24, 2077-2088 doi:10.1038/cdd.2017; published online 8 September 2017
1,2
Sarcopenia is characteristic of aged (≥75-years old) people and represents a major health problem and an important burden for health systems because of the growing lifespan in advanced countries. Histologically, sarcopenic muscles show hypotrophic myofibers (mostly type II myofibers) and infiltration with adipose and, at later stages, fibrotic tissue and decreased numbers of satellite cells (SCs), 3 the adult stem cells of skeletal muscles located between the sarcolemma and the basal lamina. 4 SCs are essential for the maintenance of muscle mass. 4 Sarcopenia may be either secondary to chronic inflammatory statuses, diabetes, hormonal alterations, vascular disturbances and immobilization, 2 or primary, occurring in otherwise healthy, usually aged persons. 1 The pathogenesis of primary sarcopenia is not completely understood. Extrinsic, niche-related factors and intrinsic, cell-autonomous factors concur to determine changes in SCs, ultimately leading to reduced SCs' ability to maintain muscle mass. [4] [5] [6] [7] [8] [9] [10] [11] Accumulation of reactive oxygen species (ROS) characterizes activated, aged SCs/proliferating aged myoblasts; possibly, ROS overproduction, owing to either altered mitochondrial function or defective ROS management, is one main cause of sarcopenia. 12, 13 ROS overproduction might determine the aberrant p38 MAPK activity, deregulated p16 (INK4a) expression and JAK-STAT signaling and defective autophagy detected in aged SCs and suggested to be responsible for their altered proliferation and differentiation properties. [7] [8] [9] [10] [11] Fat accumulation is observed in denervated muscle and atrophic muscle of elderly people. 14, 15 The origin of infiltrating adipocytes resides in fibro-adipogenic precursors, [16] [17] [18] nonmyogenic mesenchymal progenitor cells 19 and SCs themselves. [19] [20] [21] [22] Notably, ROS accumulation characterizes adipogenesis, 23 and oxidative stress induces adipogenic differentiation of skeletal myofiber-associated cells. 24 Myoblasts and adipocytes share a common progenitor cell. Physiologically, mesenchimal stem cells differentiate into Myf5 + myogenic lineage progenitors under the action of bone morphogenetic protein 7 (BMP-7), a TGF-β family member.
Myf5
+ progenitors can generate myoblasts and brown adipocytes, 26 and PAX7-expressing cells, that is SCs and their immediate progeny (i.e., proliferating myoblasts), can generate both brown adipocytes and skeletal muscle. 27 Cell fate decision depends on levels of BMP-7. Persisting BMP-7 causes Myf5 + progenitors to differentiate into brown adipocytes by repressing the expression of the adipogenic inhibitors, Necdin (Ndn) and preadipocyte factor 1 (Pref1) and inducing the key molecular determinant, PRD1-BF1-RIZ1 homologous domain-containing 16 (PRDM-16). 28, 29 In turn, PRDM-16 triggers the activation of the complete brown adipogenesis program and blocks the induction of myoblastspecific genes such as Myf5 and Myod1. In the presence of low or no BMP-7 Myf5
+ progenitors proceed along the myogenic lineage by increasing Myod1 expression levels. 25 S100B protein is a Ca 2+ -binding protein of the EF-hand type 30 expressed in mature myofibers, SCs, proliferating myoblasts and differentiated myocytes.
31 S100B associates with microtubules and type III intermediate filaments and negatively regulates their assembly state in a Ca 2+ -dependent manner, 32, 33 which might be important during cell division and myocyte fusion. S100B was shown to modulate myoblast differentiation by activating the IKKβ/NF-κB pathway, upregulating Yin Yang 1 (YY1), and inhibiting the expression of MyoD, a muscle-specific transcription factor responsible for the induction of the essential myogenic transcription factor, myogenin. 31 Upon transfer from growth medium (GM) to differentiation medium (DM), myoblasts transiently downregulate S100B expression in a p38 MAPK-and proteasome-dependent manner; S100B downregulation at the beginning of the myogenic differentiation process is permissive for myogenesis. 34, 35 Interestingly, myoblasts derived from aged human SCs, which are proliferation and differentiation defective, show upregulated S100B levels, and knockdown of S100B partly reverts aged human myoblasts to a young phenotype. 34 Thus, elevated S100B levels contribute, at least in part, to the characteristically low myogenic potential of aged myoblasts.
In the present work we sought to investigate the relationship between chronic oxidative stress and S100B levels in myoblasts, and consequences of upregulation of S100B in terms of cell lineage identity. We found that (1) chronic oxidative stress is a potent inducer of S100B expression via NF-κB activation; (2) upregulated S100B causes myoblasts to convert into brown adipocytes via an NF-κB/YY1 axis that negatively regulates the promyogenic and anti-adipogenic miR-133 with consequent accumulation of the pro-brown adipogenic transcription regulator, PRDM-16, and an NF-κB/ YY1/BMP-7 axis with resultant BMP-7 autocrine activity; (3) S100B levels are elevated in brown adipocytes obtained by culturing myoblasts in adipocyte differentiation medium (ADM) and S100B knockdown in myoblast-derived brown adipocytes reconverts them into fusion-competent myoblasts; and (4) muscles of geriatric but not young mice show expression of the brown adipocyte marker, uncoupling protein 1 (UCP-1) in interstitial cells and a subpopulation of myofibers, and uncoupling protein 1 (UCP-1) co-localizes with S100B at these sites.
Results
Chronic elevation of ROS levels inhibits myogenic differentiation and increases S100B levels. Paraquat (PQ) is a herbicide known to cause cell dysfunction via mitochondrial damage and ROS overproduction. 36 Treatment of C2C12 myoblasts for 72 h in GM with increasing PQ doses caused dose-dependent ROS production and reduction of cell viability at ≥ 100 μM (Figure 1a) . Subsequent experiments with PQ were performed in the presence of 100 μM PQ because at this concentration PQ caused at 72 h a~36% increase in ROS levels and a moderate (~29%) decrease in the cell number as a result of a~48% increase in the percentage of cells in the sub-G1 phase of the cell cycle (essentially apoptotic cells),~12% decrease in the percentage of cells in G0/G1 phase,~30% decrease in the percentage of cells in S phase and~100% increase in the percentage of cells in G2/M phase compared with controls ( Figure 1a ). Based on these results, in experiments performed in the presence of PQ, myoblasts were seeded at a 100% higher number in GM compared with the control to obtain comparable myoblast densities at 72 h.
Consistent with previous work, 37 chronic (72 h) treatment of C2C12 myoblasts with PQ in GM and DM caused a robust inhibition of myogenic differentiation. Specifically, PQ treatment reduced the number and size of myotubes (Figure 1b) , and levels of phosphorylated (activated) p38 MAPK (the master kinase in the myogenic differentiation process), MyoD (a muscle-specific transcription factor required for myoblast proliferation arrest and capable of inducing myogenin), myogenin (an early myogenic differentiation marker essential for myogenic differentiation) and myosin heavy chain, a late myogenic differentiation marker 38 ( Figure 1c ). PQ treatment of myoblasts for 72 h in GM only was sufficient to significantly inhibit p38 MAPK and myogenic differentiation (Supplementary Figure S1a ,b). The reduced p38 MAPK phosphorylation extent in PQ-treated myoblasts was likely dependent on ROS-dependent induction of the phosphatase, MKP-1 (Dusp1) 39 ( Figure 1d ). Also, PQ treatment of myoblasts in GM only resulted in enhanced NF-κB(p65) phosphorylation (activation) levels (Supplementary Figure S1b) as previously reported, 40 and in higher levels of S100B compared with controls (Supplementary Figure S1b) . Similar levels of S100B were detected in PQ-treated and control myoblast cultures after 72 h in DM (Figure 1c) . However, whereas in control cultures S100B was highly expressed in myotubes and myogenin + myocytes but not in non-differentiated (myogenin -) myoblasts (Supplementary Figure S1c) as reported, 31, 32 in PQ-treated cultures S100B was present in non-fused myogenin -myoblasts that represented the vast majority of the cells in this condition (Supplementary Figure S1c) . Persistence of S100B in non-differentiated (myogenin -), non-fused myoblasts in DM likely depended on the strongly reduced activation of p38 MAPK 31, 32 consequent to chronic PQ treatment (Figure 1c and Supplementary Figure S1b) and/ or other concurring events (see Figure 3a) . Culturing myoblasts in the presence of the antioxidant, trolox (TLX), significantly reduced PQ-induced effects on ROS production (Supplementary Figure S2a) , MyoD and S100B levels (Supplementary Figure S2b) , and NF-κB(p65) transcriptional S100B promotes myoblast-brown adipocyte transition G Morozzi et al activity (Supplementary Figure S2c) . Thus, we tentatively ascribed the anti-myogenic effect of PQ to chronic ROS production and the enhanced activity of the anti-myogenic NF-κB(p65) and S100B.
Chronic oxidative conditions cause myoblast-brown adipocyte transition via upregulation of S100B. ROS accumulation characterizes adipogenesis. 23 As PQ-treated myoblasts in GM accumulated ROS (Figure 1a) , showed high S100B levels (Supplementary Figure S1b) and low MyoD levels, and presented little or no expression of myogenic markers in DM (Figure 1c and Supplementary Figure S1c) , we asked whether PQ and/or S100B might promote myoblast-adipocyte transition. PQ treatment of C2C12 myoblasts for 72 h in GM resulted in staining of 490% of cells with Oil Red O (ORO), that detects lipid droplets and marks adipocytes, with minimal ORO staining of control cells (Figures 2a and e) . Similarly, the vast majority of myoblasts cultured for 72 h in DM following PQ treatment showed ORO staining compared with a few ORO-stained non-fused cells in control cultures (Figure 2a ). Culturing myoblasts in the presence of TLX reduced PQ-induced effects on lipid droplet formation (Supplementary Figure S2d) . Thus, PQ treatment might cause myoblast-adipocyte transition via ROS production.
We asked whether the elevated levels of S100B detected in PQ-treated myoblasts (Figure 1c and Supplementary Figure  S1b ,c) might have a role in myoblast-adipocyte transition. Transient transfection with bovine S100b (Figure 2b ) resulted in ORO staining of 470% C2C12 myoblasts after 72 h in GM (Figure 2c ). Also, L6C8 myoblasts, a clone of rat L6 myoblasts stably overexpressing S100B and incapable of differentiating into myocytes and of forming myotubes, 31 were nearly 100% ORO stained after 72 h in GM as opposed to essentially no ORO staining in control (L6C11) myoblasts (Figure 2d ). Moreover, knockdown of S100B in PQ-treated C2C12 myoblasts resulted in little if any ORO staining (Figure 2e ). Thus, S100B appears to be intrinsically endowed with proadipogenic properties in myoblasts and the proadipogenic effect of PQ in myoblasts might depend on S100B overexpression in part.
Next, we assessed in C2C12 myoblasts expression levels of factors known to regulate the commitment of Myf5 + progenitors to myoblasts or brown adipocytes, including the peroxisome proliferator-activated receptor gamma (PPARγ) co-activator, Prdm16, a zinc-finger transcriptional regulator necessary and sufficient to establish the identity of the brown adipose tissue lineage, 26, 28 and BMP-7 that, when released, induces Prdm16 and PPARγ co-activator 1 α (Pgc1a) to increase the brown, but not white, adipose differentiation. 29 PQ-treated myoblasts in GM showed higher levels of S100b, the brown adipogenic factors, Bmp7, Prdm16 and Pgc1a, and the brown adipocyte marker, Ucp1, lower levels of the antiadipogenic factors Pref1 and Ndn, and reduced levels of the myoblast-specific genes, Pax7 and Myod1 compared with controls ( Figure 2f ). Culturing myoblasts in the presence of TLX significantly reduced PQ-induced effects on S100b, BMP-7 (mRNA and protein), Prdm16 and UCP-1 (mRNA and protein) levels (Supplementary Figure S2e) . Thus, chronic oxidative conditions switched myoblasts towards a brown adipocyte phenotype. Transient transfection of C2C12 myoblasts with S100b also resulted in increased levels of Prdm16, Figure 1 Chronic elevation of ROS levels inhibits myogenic differentiation and increases S100B levels. (a) C2C12 myoblasts were cultured in GM for 72 h in the presence of increasing doses of PQ. ROS production (left panel) and cell viability (middle panel) were measured and percentages of apoptotic (sub-G1) cells and cells in the G0/G1, S and G2/M phase of the cell cycle were calculated (right panels). (b) C2C12 myoblasts were cultured in GM for 72 h in the absence or presence of 100 μM PQ and then transferred to DM for another 72 h again in the absence or presence of 100 μM PQ. Cultures were subjected to May-Grunwald Giemsa staining. (c) Conditions were as in (b) except that cell lysates were subjected to western blotting for the detection of the indicated proteins. Tubulin was used as loading control. Figure S3b) compared with controls. At last, knockdown of S100B in PQ-treated C2C12 myoblasts in GM reversed the PQ-induced increase in Bmp7, Prdm16, Pgc1a and Ucp1 levels ( Figure 2j ) and PQ-induced increase in NF-κB transcriptional activity and decrease in MyoD levels (Figure 2k) . Thus, at relatively high levels S100B might promote myoblastbrown adipocyte transition.
S100B and NF-κB(p65) regulate each other levels and YY1 levels. The anti-myogenic effect of intracellular S100B relies on its ability to stimulate NF-κB(p65) activity and NF-κB (p65)-dependent inhibition of MyoD expression 31 (also see Figures 2g,h and k) . We found that S100B expression in C2C12 myoblasts is in turn positively regulated by NF-κB (p65). Indeed, inhibition of NF-κB(p65) activity by treatment of C2C12 myoblasts with the NF-κB(p65) inhibitor, sulfasalazine (SSN), reduced S100B mRNA and protein levels in control and PQ-treated myoblasts in GM (Figure 3a) in agreement with the presence of four NF-κB(p65) recognition sites in the S100b promoter (1000 bp upstream of the transcription initiation site) and NF-κB(p65)-dependent induction of S100B expression in other experimental settings. 41 Thus, a reciprocal regulation of S100B and NF-κB(p65) might occur in myoblasts whereby S100B stimulates NF-κB(p65) activity and NF-κB(p65) upregulates S100B.
Notably, either PQ treatment (Figure 3a ) or S100b transfection (Figure 3b ) of C2C12 myoblasts caused upregulation of mRNA and protein levels of YY1, a transcriptional repressor induced by NF-κB(p65) with anti-myogenic activity. 42 Inhibition of NF-κB (p65) reversed PQ effects on YY1 and BMP-7 mRNA and protein levels and Pref1, Prdm16 and Ucp1 levels ( Figure 3a ) and reduced lipid droplet formation in PQ-treated C2C12 myoblasts and untreated L6C8 myoblasts (Figure 3c ). Treatment with TLX also reduced PQ-induced upregulation of YY1 (Supplementary Figure S2f) . Further, L6C8 myoblasts showed higher Yy1 levels compared with L6C11 myoblasts (Figure 3d ) as reported, 31 and treatment of L6C8 myoblasts with SSN reduced Yy1, Prdm16, Bmp7 and Pgc1α levels (Figure 3d) . Lastly, treatment of L6C8 myoblasts with a specific YY1 siRNA inhibited lipid droplet formation (Figure 3e ) and reduced Bmp7 and Prdm16 levels (Figure 3f) . Thus, S100B, induced by NF-κB (p65), might activate NF-κB(p65) in myoblasts to increase its own levels and levels of the proadipogenic BMP-7, Prdm16 and Pgc1α, of Ucp1 and of the anti-myogenic and, as shown here for the first time, brown adipogenic YY1, and to decrease the anti-adipogenic Pref1. S100B reduces levels of miR-133, a promyogenic and anti-adipogenic factor. The muscle-specific miRNA, miR-133, regulates myoblast proliferation and differentiation 43, 44 and prevents myoblast-brown adipocyte transition by repressing Prdm16 expression. 45, 46 The observation that Yy1 negatively regulates the expression of muscle-specific miRNAs including miR-133 47 and the finding that S100B upregulates YY1 31 (also see Figure 3b ) prompted us to investigate potential interactions between S100B and miR-133 in the context of myoblast-brown adipocyte transition. Either PQ treatment (Figure 4a ) or transient transfection with S100b (Figure 4b ) caused downregulation of miR-133 in C2C12 myoblasts in both GM and DM, and inhibition of NF-κB with SSN in PQ-treated C2C12 myoblasts restored miR-133 levels ( Figure 4c) . Thus, the pro-brown adipogenic effects of S100B and NF-κB might be mediated by repression of miR-133 likely via upregulation of YY1.
Chronic oxidative conditions and/or upregulation of S100B increase BMP-7 secretion with resultant autocrine pro-brown adipogenic effects of BMP-7. Culture media of C2C12 and L6C11 myoblasts in GM contained minimal if any BMP-7, whereas culture media of PQ-treated C2C12 myoblasts and L6C8 myoblasts contained large BMP-7 amounts (Figure 5a ). Culturing PQ-treated C2C12 myoblasts in the presence of a BMP-7-neutralizing antibody caused a robust decrease in ORO staining compared with non-immune IgG-treated controls (Figure 5b ) and reversed PQ effects on S100b, Pref1, Yy1, Prdm16 and Ucp1 levels (Figure 5c ). Similarly, blocking extracellular BMP-7 in S100b-transfected C2C12 myoblasts reduced Bmp7, Prdm16, Pgc1α and Ucp1 levels compared with the control (Figure 5d ). Also, culturing L6C11 myoblasts in the presence of conditioned medium from L6C8 myoblasts caused lipid droplet formation (Figure 5e ) and enhanced Yy1, Bmp7, Prdm16 and Pgc1α levels (Figure 5f ). Thus, PQ-and S100B-induced myoblast-brown adipocyte transition might also depend on induction and secretion of BMP-7 and autocrine BMP-7-dependent induction of Bmp7 itself, Yy1, Prdm16, Pgc1α and S100b, and BMP-7 effects might be mediated by S100B in part. The fold changes ( ± S.E.M.) (N = 3) were determined (f, g, j and h, i, k right panels). *, ** and *** significantly different from control (Po0.05, Po0.01 and Po0.001, respectively). Bars in (a), (c-e) = 100 μm S100B promotes myoblast-brown adipocyte transition G Morozzi et al
Myoblasts from aged sarcopenic humans show features of brown adipocytes. Myoblasts from sarcopenic humans are differentiation defective and show high levels of S100B and low p38 MAPK phosphorylation levels compared with myoblasts from non-sarcopenic subjects. 34 Myoblasts from aged sarcopenic but not young subjects showed ORO staining in both GM and DM (Figures 6a and b) and higher YY1 and BMP-7 levels compared with young subjects (Figure 6c ). Thus, myoblasts from sarcopenic subjects resemble PQ-treated C2C12 myoblasts in terms of S100B, *, ** and *** significantly different from control (Po0.05, Po0.01 and Po0.001, respectively). Bars in (c, e) = 100 μm YY1, and BMP-7 levels, p38 MAPK phosphorylation levels 34 and of lipid droplet formation, which is in agreement with the chronic oxidative conditions that characterize sarcopenic myoblasts. 48 Thus, chronic oxidative conditions might increase S100B levels, which in turn might promote myoblast-brown adipocyte transition in aged human myoblasts. S100B becomes upregulated in an NF-κB-dependent manner in myoblasts cultured in ADM promoting myoblast-brown adipocyte transition, and co-localizes with UCP-1-expressing cells and myofibers in geriatric muscles. C2C12 myoblasts show features of pluripotent mesenchimal stem cells and exhibit myogenic, osteogenic and adipogenic differentiation markers. 20 When exposed to a cocktail of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, dexamethasone and insulin (ADM), 49 C2C12 myoblasts differentiate into adipocytes. 50 Culturing C2C12 myoblasts in ADM caused upregulation of S100B and UCP-1 (mRNA and protein), Yy1, Bmp7 and Prdm16 levels and enhancement of NF-κB transcriptional activity ( Figure 7a ) and formation of lipid droplets (Figure 7b ). Inhibition of NF-κB with SSN or S100B knockdown robustly reduced ADM effects on S100b, Ucp1, Yy1, Bmp7 and Prdm16 levels and caused a~75% and 50% reduction of ORO-stained cell numbers, respectively, with accompanying change of the cell shape from round to fusiform (Figures 7a and b) . Thus, S100B and NF-κB appear to be important molecular determinants of ADM-induced C2C12 differentiation into brown adipocytes. Further, shifting cells from ADM to GM for 3 days resulted in no major changes compared with the ADM condition, however S100B knockdown caused myotube formation (Figure 7b ). Thus, reducing S100B levels in myoblastderived brown adipocytes was sufficient for reverting them to fusion-competent myoblasts even in GM. Likewise, switching primary mouse myoblasts to ADM led to increased S100b, Ucp1, Yy1, Bmp7, Pgc1α, Prdm16, S100B, BMP-7, YY1 and UCP-1 levels (Supplementary Figure S3c) along with increased ORO staining (Supplementary Figure S3d) . Also, muscles of geriatric (28 months old) and young (2 months old) mice showed expression of S100B in a subpopulation of myofibers as expected 31 with higher levels in geriatric myofibers (Figures 7c and d) . Notably however, geriatric but not young muscles showed co-expression of S100B and UCP-1 in interstitial cells and, unexpectedly, in the S100B + subpopulation of myofibers including thin, regenerating (i.e., centrally nucleated) myofibers (Figure 7c ). Geriatric muscle tissue contained UCP-1 by western blot analysis as opposed to the almost complete absence of UCP-1 in young muscles (Figure 7d ).
Discussion
Chronic oxidative conditions induce adipogenic differentiation of skeletal myofiber-associated cells, 24 and overproduction of ROS consequent to either altered mitochondrial function or defective ROS management, is considered characteristic of activated, aged SCs/proliferating aged myoblasts and hence one main cause of sarcopenia. [11] [12] [13] In the present report we have shown that chronic oxidative conditions cause myoblastbrown adipocyte transition via NF-κB(p65)-dependent upregulation of S100B and S100B-dependent activation of an NF-κB/YY1 axis, leading to downregulation of the promyogenic and anti-adipogenic myomiR, miR-133 and consequent 45, 46 upregulation the essential brown adipogenic Prdm16 (Figure 7e) . The S100B/NF-κB(p65)/YY1 axis also upregulates the brown adipogenic BMP-7 and the resultant enhanced extracellular levels of BMP-7 upregulate Bmp7 itself, S100b and Prdm16 (Figure 7e) . Notably, Bmp7 expression was shown to be positively regulated by NF-κB (p65) in other experimental settings. 51 Moreover, culturing C2C12 myoblasts in ADM results in myoblast-brown adipocyte transition and enhanced NF-κB activity and S100B expression. ADM-induced upregulation of S100B plays an important role in this transition as S100B knockdown in myoblastderived brown adipocytes causes their reversal to fusion-competent myoblasts. Interestingly, myoblasts derived from isolated aged hu-SCs show features of brown adipocytes, and primary mouse myoblasts behave essentially as do C2C12 myoblasts in terms of conversion to brown adipocytes when transfected with S100b or switched to ADM. Lastly, muscles of geriatric but not young mice co-express S100B and Previous work has shown that YY1 is required for mitochondrial morphology and bioenergetic function in skeletal muscle tissue 52 and recently, YY1 in brown adipose tissue has been shown to activate the canonical thermogenic and uncoupling gene expression program. 53 Our novel results suggest that YY1, induced by S100B via NF-κB in chronic oxidative conditions or under the autocrine action of BMP-7 in S100B-overexpressing myoblasts, promotes myoblast-brown adipocyte transition, which might have important implications in the pathophysiology of primary sarcopenia. In this regard, it is notable that myoblasts derived from aged sarcopenic humans show elevated levels of S100B and YY1, which might reduce their myogenic potential by driving their transition to brown adipocytes. Incidentally, we show that S100B/NF-κB-induced YY1 promotes myoblast-brown adipocyte transition as opposed to the inhibitory effects of YY1 on the transition of preadipocytes to white adipocytes. 54 Both microenvironmental conditions 5, 6 and cell intrinsic properties [7] [8] [9] [10] [11] are responsible for the reduced myogenic potential of myofiber-associated stem cells seen in sarcopenia. A reduced ability to manage ROS appears to be one major cause of muscle wasting in elderly people [11] [12] [13] and, possibly, Figure 5 Chronic oxidative conditions and/or upregulation of S100B expression increase BMP-7 secretion and autocrine pro-brown adipogenic effects of BMP-7. (a) C2C12 myoblasts were cultured in GM for 72 h in the absence or presence of 100 μM PQ or transfected with S100b. Parallel L6C11 and L6C8 myoblasts were cultured in GM for 72 h. Culture media were collected, TCA precipitated and analyzed for expression of BMP-7 by western blotting. (b) C2C12 myoblasts were cultured in GM for 72 h in the absence or presence of 100 μM PQ ± non-immune IgG (control and PQ) or neutralizing anti-BMP-7 antibody (4 μg/ml). Cells were stained with ORO. of the aforementioned alterations in aged SCs. 48 Our present results suggest that ROS/NF-κB-induced accumulation of S100B in aged SCs/myoblasts might represent an important piece of the complex molecular mosaic behind sarcopenia. Indeed, S100B-induced myoblast-brown adipocyte transition can be reversed by S100B knockdown. Thus, we propose that the anti-myogenic properties of intracellular S100B 31,34 might be exerted (1) via the known ability of NF-κB/YY1 to repress MyoD and myogenin expression 40, 42 likely through NF-κB/ YY1-induced reduction of expression of the promyogenic and anti-adipogenic myomiR, miR-133, with resultant upregulation of Prdm16 levels, and (2) via NF-κB/YY1-mediated upregulation of BMP-7 and resultant BMP-7-dependent myoblastbrown adipocyte transition.
Fat accumulation is a major pathogenic factor in sarcopenia, 3 and S100B is found in high abundance in white adipocytes, 55 brown adipocytes, particularly paucilocular and unilocular brown adipocytes, 56 and in breast, cardiac and intraosseous hibernoma. [57] [58] [59] As shown here, in geriatric muscles S100B co-localizes with UCP-1 + interstitial cells, i.e., bona fide brown adipocytes, and in a subpopulation of medium-sized myofibers and regenerating myofibers. Collectively, our results suggest that ROS/NF-κB-induced S100B might be a major molecular determinant of myoblast-brown adipocyte transition having an important role in the brown adipocyte-like features of myoblasts from sarcopenic humans and a potential therapeutic target. The previously unreported finding of UCP-1 expression within geriatric myofibers calls for an in-depth investigation of the functional role of UCP-1 and the S100B-UCP-1 interplay in these myofibers.
Materials and Methods
Antibodies and oligonucleotide sequences. Antibodies and oligonucleotide sequences are listed in Supplementary Experimental Procedures (Supplementary Table S1 and Supplementary Table S2 , respectively).
Cell culture. C2C12 and primary myoblasts were seeded in Dulbecco's modified Eagle medium (DMEM) (Invitrogen) supplemented with 20% FBS (Gibco Life Technologies, Milan, Italy), 100 U/ml penicillin and 100 mg/ml streptomycin (GM), in an H 2 O-saturated 5% CO2 atmosphere at 37°C and left undisturbed for 72 h. Where required, myoblasts were shifted either to DMEM supplemented with 2% horse serum (HS) (Euroclone, Milan, Italy), 100 U/ml penicillin, and 100 mg/ml streptomycin (DM) and cultured for 24-72 h, or to DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin containing 0.5 mM phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, 1 μM dexamethasone and 850 nM/ml insulin (all from Sigma-Aldrich S.r.l., Milan, Italy) (ADM) and left undisturbed for 3 days. L6C11 and L6C8 rat myoblasts 31 were seeded in DMEM supplemented with 10% FBS and antibiotics as reported 31 and cultured for 72 h. Where required cells were treated with PQ (Sigma) in the absence or presence of either 100 μM SSN (Sigma-Aldrich S.r.l.) or 100 μM TLX (Sigma-Aldrich S.r.l.). Myoblast derived from human SCs were provided by the University of ChietiPescara, Italy, and were obtained from Vastus lateralis muscle biopsies of young and aged healthy untrained humans, following informed consent, enrolled in a study approved by the Ethics Committee for Biomedical Research of the University of Chieti-Pescara, Italy, (PROT 1884 COET) and complying with the Declaration of Helsinki (amended in 2000). Human myoblasts were grown in HAM's F-10 (Gibco Life Technologies) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 50 μg/ml gentamycin (GM), in an H 2 O-saturated 5% CO2 atmosphere at 37°C. To induce myogenic differentiation, human myoblasts were transferred to HG-DMEM supplemented with 2% HS, antibiotics as above, 10 μg/ml insulin and 100 μg/ml apotransferrin for 3 days. May-Grunwald Giemsa and ORO staining and immunofluorescence. Cells were fixed for 7 min with cold methanol, washed three times with deionized water, dried in a heater and subjected to May-Grunwald Giemsa staining following a standard procedure. For ORO staining, cells were fixed with paraformaldehyde (Sigma-Aldrich S.r.l.) (4% in PBS) for 10 min at room temperature and stained either with ORO (Sigma-Aldrich S.r.l.). Cells were then washed 2-3 times with water and incubated for 2 min with Hematoxylin (Bioptica, Milan, Italy) and washed until the water was clear. The cells were viewed in a phase contrast microscope (Olympus IX51) equipped with a digital camera (Olympus C-5050 ZOOM), and the images were acquired at 20x magnification. For double immunofluorescence, the cells were fixed with 4% paraformaldehyde in PBS for Western blotting. Cells were homogenized in 50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, in the presence of a mixture of protease inhibitors (Roche Applied Science, Milan, Italy). The amount of protein in each samples was determined by Bradford assay and equal amounts of protein were size-separated by SDS-PAGE. The primary antibodies used in immunoblot analyses are listed in Supplementary Table S1 . After incubation with the appropriate HRP-conjugated secondary antibodies (Santa Cruz Biotechnology), the immune reaction was developed by enhanced chemiluminescence (SuperSignal West Pico, Life Technologies, Milan, Italy). C-DiGit Blot Scanner (Lincoln, Nebraska, USA) was used for blot analysis.
Transfection assay. For NF-κB transcriptional activity, myoblasts in GM were transfected with NF-κB-luc reporter gene using jetPEI (Polyplus Transfections) as recommended by the manufacturer. After 24 h the cells were subjected to Firefly Luciferase Assay (Mirus, Madison, WI, USA) as recommended by the manufacturer. For transfection with bovine S100b, myoblasts in GM were transfected with pGMTSV-NEO S100B or empty vector for 24 h using jetPEI (Polyplus Transfections, New York, NY, USA) as recommended by the manufacturer. For siRNA transfection, myoblasts in GM were transfected with either S100B siRNA (Dharmacon, Carlo Erba Reagents Srl, Milan, Italy, ON-TARGET plus mouse S100B), YY1 siRNA (Gibco Life Technologies) or negative controls (Dharmacon, siRNA SMARTpoll control for S100B, and Invitrogen, Negative Universal Control Stealth for YY1) for 24 h using INTERFERin (Polyplus Transfections) as recommended by the manufacturer.
Real-time PCR. Total RNA was extracted from cell cultures using TRIsure (Bioline) according to the manufacturer's instructions and reverse-transcribed with M-MLV Reverse Transcriptase (Life Technologies, Milan, Italy). Real-time PCR analyses of mRNA contents were performed on Stratagene Mx3000P (Agilent Technologies, Santa Clara, CA, USA) by using HOT FIREPol EvaGreen qPCR Mix Plus (ROX) ready-to-use solution (Solis BioDyne, Tartu, Estonia) in the presence of the primer sets in Supplementary Table S2 . Gapdh was used as an internal standard.
Animal treatment. C57BL/6 mice were obtained from Charles River. Primary myoblasts were isolated from 3-d-old WT (C57BL/6) pups and cultivated as described, 60 and characterized by immunofluorescence using a polyclonal anti-cMet antibody (Santa Cruz Biotechnology) after fixation with cold methanol for 7 min at -20°C. Greater than 95% cells were c-Met-positive. GC muscles were removed, fixed in 4% formalin in PBS (pH 7.2) and paraffin embedded for immunofluorescence analyses. Approval of use of animals was obtained by the Ethics Committee of the Perugia University and the Ministero della Salute, Italy. All methods were performed in accordance with the relevant guidelines and regulations of the Perugia University and the Ministero della Salute, Italy.
Immunofluorescence. Paraffin sections of GC muscles were cut at 4 μm, deparaffinized with xylene, rehydrated in a graded ethanol series. Antigen retrieval was obtained by boiling for 2 h in 10 mM citric acid buffer (pH 6.0), and depletion of endogenous peroxidase was accomplished by treatment with 3% H 2 O 2 in methanol for 30 min. Sections were washed with PBS, pH 7.4, incubated for 1 h with blocking buffer (PBS containing 0.04% Triton X-100, 10% HS and 1% BSA) and then probed with mouse monoclonal anti-S100B antibody (R&D Systems, Minneapolis, MN, Toll Free USA, Canada) or rabbit polyclonal anti-UCP-1 antibody (Abcam ab10983). The antibodies were diluted (1:50) in 1% BSA in PBS and the sections incubated overnight in a humid chamber at 4°C. After several washings with Tween-PBS, the sections were incubated with appropriate secondary fluorophore-antibodies (1:100 in 1% BSA in PBS; Gibco Life Technologies) for 2 h. The sections were then rinsed with Tween-PBS. Nuclei were counterstained with DAPI. After rinsing, samples were mounted with fluorescent mounting medium (Dako Corporation) and viewed in an epifluorescence microscope (Leica DMRB) equipped with a digital camera.
Statistical analysis. Each experiment was repeated at least three times. Representative experiments are shown unless stated otherwise. The data were subjected to analysis of variance with SNK post hoc analysis using a statistical software package (GraphPad Prism version 4.00, GraphPad Software, Inc., La Jolla, CA, USA). Data are the results of at least three independent experiments and are expressed as mean ± S.E.M.
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